BioGaia Pharma
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
PO Box 3242, Stockholm, Se, 103 64, Swed...Phone Number
+46 706313361Website
www.biogaiapharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BioGaia Pharma
BioGaia Pharma specializes in developing novel live biotherapeutics that leverage the microbiome to address a wide range of medical conditions, including diarrhoea, diabetes, and Alzheimer's. Their research focuses on understanding the relationship between microbiome dysbiosis and various diseases, utilizing advanced analytical tools to establish causal links. The company aims to create microbial therapies that can effectively influence health through multiple biological pathways. They engage in collaborative development partnerships to enhance their innovative solutions in microbiome research and diagnostics.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioGaia Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BioGaia Pharma is spiking on competitors!
BioGaia Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BioGaia Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on BioGaia Pharma recently announced quarterly report
Funding: Get notified immidiatlly once BioGaia Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BioGaia Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BioGaia Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at BioGaia Pharma
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
BioGaia Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioGaia Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioGaia Pharma.
BioGaia Pharma Tech Stack
A closer look at the technologies used by BioGaia Pharma
See more technologies
BioGaia Pharma News & Media
BioGaia Pharma announces First Patient Enrolled in Phase I Clinical Study Evaluating BGP014 in mild to moderate ulcerative colitis (AUCH-1).
BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into AUCH-1 in February 2022. “We are pleased to have taken a significant step in the development of improved therapeutic options in ulcerative colitis treatment,” said Nigel Titford CEO of BioGaia Pharma. BGP014 is targeted to Ulcerative ColitiBioGaia Pharma announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)
BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into OIC-1 in January 2022. BGP345A looks to treat constipation in patients receiving opioid therapy for prescribed pain treatment. Opioids are an essential option for chronic pain, primarily back pain, rheumatism or post-operative pain, where nBioGaia Pharma secures approval for two clinical trials for its pharmaceutical candidates
BioGaia Pharma has received formal approval from relevant authorities to proceed with both of its planned clinical trials. The trials are the next phase in the development of BioGaia Pharma’s two pharmaceutical product candidates. The biologics both contain a single strain live microbial as API. Recruitment will start during late 2021. The first program BGP014 is for Ulcerative Colitis (UC). UC is a debilitating condition characterised by chronic inflammation in the intestinal tract affecting ro
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioGaia Pharma
Sign Up For FreeTo access detailed company insights
BioGaia Pharma specializes in developing novel live biotherapeutics that leverage the microbiome to address a wide range of medical conditions, including diarrhoea, diabetes, and Alzheimer's. Their research focuses on understanding the relationship between microbiome dysbiosis and various diseases, utilizing advanced analytical tools to establish c... Read More
